Business representatives announce that the second phase of Shanghai BioEngine's production base in Jinshan district has started operations. [Photo/Pudong Times]

As the scientific research results of the biological medicine industry in Zhangjiang Science City of China (Shanghai) Pilot Free Trade Zone enter mass production, Shanghai is building a mechanism to allow industrial parks across the metropolis to undertake the commercialization of Zhangjiang's biological R&D achievements.

Under such a mechanism, the second phase of Shanghai BioEngine's production base in Jinshan district recently started operations.

The production base combines culture medium manufacturing, quality control, engineering, material procurement and logistics. It boasts five smart production lines that can produce 55 million liters of powder culture medium and 250,000 liters of liquid culture medium annually.

In addition, the base will tailor its products to international standards, and obtain registration certificates from the National Medical Products Administration and the US Food and Drug Administration, to provide high-quality culture medium for global biomedical products like antibodies, vaccines and cell treatment.

BioEngine was founded in Zhangjiang in 2014 by Tan Wensong, professor of East China University of Science and Technology. The company has since been devoted to R&D of animal cell cultivation technology, technical services and culture medium supply.